AMENDMENTS TO THE CLAIMS

In the Claims:

The following listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently amended) A glucagon-like peptide-1 receptor agonist having the following structural formula:



wherein, each of Ar_1 and Ar_2 independently is ~~phenyl or~~ substituted phenyl, and the substituent groups ~~of the said substituted phenyl is~~ are one, two or three groups optionally selected from the following ~~group~~ groups: ~~alkyl; hydroxyl;~~ substituted alkoxyl or alkylamino which contains the substituent groups including halogen, alkoxyl or hydroxyl; substituted alkanoylxy or alkanoylamino which contains the substitutent groups including halogen, alkoxyl or hydroxyl; ~~C_2-C_6 alkenyl substituted with oxygen or amine, phenyl, benzyl,~~ C_2-C_6 enoyl, C_3-C_6 cycloalkanoyl, benzoyl, ~~substituted benzoyl which contains optional one, two or three substituent groups including alkoxyl and alkanoylamino,~~ benzyloyl, thenoyl, tert-butoxycarbonyl, adamantane formoxyl, and mandeloyl; alkoxyl; alkylamino; ~~cycloalkoxyl; cycloalkylamino; amino; amide;~~ alkoxycarbonyl; cycloalkoxycarbonyl; alkanoylxy; alkanoylamino; cycloalkanoylxy; cycloalkanoylamino; ~~carbamido; urylene;~~ alkanoyl; ~~nitro; carboxyl; and aldehyde group;~~

X is O~~, S, or NH~~; and

Y is O~~ or S~~.

2. (Currently amended) The glucagon-like peptide-1 receptor agonist according to the claim 1, ~~being characterized in that~~ wherein:

when Ar_1 is 

,

wherein R_1 is any one of the following substituent groups: ~~H; alkyl; substituted alkyl which contains the substituent groups including halogen, alkoxyl or hydroxyl; C_2-C_6 alkenyl; C_3-~~

~~C_6-cycloalkyl; phenyl; benzyl;~~ alkanoyl; substituted alkanoyl which contains the substituent groups including halogen, alkoxyl or hydroxyl; C_2-C_6 enoyl; C_3-C_6 cycloalkanoyl; benzoyl; substituted benzoyl which contains optional one, two or three substituent groups including alkoxyl and alkylamino; tert-butoxycarbonyl; ~~benzyloyl;~~ thenoyl; adamantane formoxyl; and mandeloyl; and X_1 is O or NH,

Ar_2 is 

,

wherein R_2 is any one of the following substituent groups: ~~H; alkyl; substituted alkyl which contains the substituent groups including halogen, alkoxyl or hydroxyl; C_2-C_6 alkenyl; C_3-C_6 cycloalkyl; phenyl; benzyl;~~ alkanoyl; substituted alkanoyl which contains the substituent groups including halogen, alkoxyl or hydroxyl; C_2-C_6 enoyl; C_3-C_6 cycloalkanoyl; benzoyl; substituted benzoyl which contains optional one, two or three substituent groups including alkoxyl and alkylamino; tert-butoxycarbonyl; ~~benzyloyl;~~ thenoyl; adamantane formoxyl; and mandeloyl; and X_2 is O or NH;

or Ar_2 is 

,

wherein each of R_3 and R_4 independently is any one of the following substituent groups: ~~H;~~ alkyl; substituted alkyl which contains the substituent groups including halogen, alkoxyl or hydroxyl; C_2-C_6 alkenyl; C_3-C_6 cycloalkyl; ~~phenyl; benzyl;~~ alkanoyl; substituted alkanoyl which contains the substituent groups including halogen, alkoxyl or hydroxyl; C_2-C_6 enoyl; C_3-C_6 cycloalkanoyl; benzoyl; substituted benzoyl which contains optional one, two or three substituent groups including alkoxyl and alkylamino; tert-butoxycarbonyl; ~~benzyloyl;~~ thenoyl; adamantane formoxyl; and mandeloyl; and X_1 is O or NH; X_2 is O or NH.

3. (Currently amended) The glucagon-like peptide-1 receptor agonist according to the claim 1, ~~being characterized in that,~~ wherein:

when Ar_1 is  ,

wherein each of R_5 and R_6 independently is any one of the following substituent groups: ~~H;~~ alkyl; substituted alkyl which contains the substituent groups including halogen, alkoxyl or hydroxyl; C_2-C_6 alkenyl; C_3-C_6 cycloalkyl; ~~phenyl; benzyl;~~ alkanoyl; substituted alkanoyl which contains the substituent groups including halogen, alkoxyl or hydroxyl; C_2-C_6 enoyl; C_3-C_6 cycloalkanoyl; benzoyl; substituted benzoyl which contains optional one, two or three substituent groups including alkoxyl and alkylamino; tert-butoxycarbonyl; ~~benzyloyl;~~ thenoyl; adamantane formoxyl; and mandeloyl; and X_1 is O or NH; X_2 is O or NH,

Ar_2 is  ,

wherein R_2 is any one of the following substituent groups: ~~H; alkyl; substituted alkyl which contains substituent groups including halogen, alkoxyl or hydroxyl; C_2-C_6 alkenyl; C_3-C_6 cycloalkyl; phenyl; benzyl;~~ alkanoyl; substituted alkanoyl which contains substituent groups including halogen, alkoxyl or hydroxyl; C_2-C_6 enoyl; C_3-C_6 cycloalkanoyl; benzoyl; substituted benzoyl which contains optional one, two or three substituent groups including alkoxyl and alkylamino; tert-butoxycarbonyl; ~~benzyloyl;~~ thenoyl; adamantane formoxyl; and mandeloyl; and X_2 is O or NH;

or Ar_2 is  ,

wherein each of R_3 and R_4 independently is any one of the following substituent groups: ~~H;~~ alkyl; substituted alkyl which contains substituent groups including halogen, alkoxyl or hydroxyl; C_2-C_6 alkenyl; C_3-C_6 cycloalkyl; ~~phenyl; benzyl;~~ alkanoyl; substituted alkanoyl which contains the substituent groups including halogen, alkoxyl or hydroxyl; C_2-C_6 enoyl; C_3-C_6 cycloalkanoyl; benzoyl; substituted benzoyl which contains optional one, two or three substituent groups including alkoxyl and alkylamino; tert-butoxycarbonyl; ~~benzyloyl;~~ thenoyl; adamantane formoxyl; and mandeloyl; and X_1 is O or NH; X_2 is O or NH.

4–8. (Canceled).

9. (Original) Use of the glucagon-like peptide-1 receptor agonist according to claim 1 as medicaments for treating the carbohydrate metabolism disturbance-related diseases such as type II diabetes, insensitivity to insulin or obesity, etc.

10. (New) The glucagon-like peptide-1 receptor agonist according to the claim 1 having the following structural formula:



,

wherein R_1 is any one of the following substituent groups: alkanoyl; substituted alkanoyl which contains the substituent groups including halogen, alkoxyl or hydroxyl; C_2-C_6 enoyl; C_3-C_6 cycloalkanoyl; benzoyl; substituted benzoyl which contains optional one, two or three substituent groups including alkoxyl and alkylamino; tert-butoxycarbonyl; thenoyl; adamantane formoyl; and mandeloyl;

each of R_2 and R_3 independently is any one of the following substituent groups: alkyl; substituted alkyl which contains substituent groups including halogen, alkoxyl or hydroxyl; C_3-C_6 cycloalkyl; alkanoyl; substituted alkanoyl which contains the substituent groups including halogen, alkoxyl or hydroxyl; C_2-C_6 enoyl; C_3-C_6 cycloalkanoyl; benzoyl; substituted benzoyl which contains optional one, two or three substituent groups including alkoxyl and alkylamino; tert-butoxycarbonyl; thenoyl; adamantane formoyl; and mandeloyl;

X is O;

Y is O;

X_1 is O;

X_2 is NH;

X_3 is O.

11. (New) The glucagon-like peptide-1 receptor agonist according to the claim 1 having the following structural formula:







or .